ReviewNature immunology2018
Approaches and advances in the genetic causes of autoimmune disease and their implications.
Review in Nature immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- A genome-wide CRISPR screen identifies the TNRC18 gene locus as a regulator of inflammatory signaling.Nature communications · 2025Article
- Genome-wide association, single-cell, and spatial transcriptomics analyses reveal the role of the STK24-expressing positive cells in LUAD progression and the tumor microenvironment, identifying STK24 as a potential therapeutic target.Journal of translational medicine · 2025Article
- Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments.Pharmacological reviews · 2025Review
- Genomic variants associated with age at diagnosis of childhood-onset type 1 diabetes.Journal of human genetics · 2024Article
- High-Resolution Structure of RNA G-Quadruplex Containing Unique Structural Motifs Originating from the 5'-UTR of Human Tyrosine Kinase 2 (TYK2).ACS omega · 2024Article
- Innate and adaptive immune abnormalities underlying autoimmune diseases: the genetic connections.Science China. Life sciences · 2023Review
- Review
- An autoimmune pleiotropic SNP modulates IRF5 alternative promoter usage through ZBTB3-mediated chromatin looping.Nature communications · 2023Article
- Thymocyte regulatory variant alters transcription factor binding and protects from type 1 diabetes in infants.Scientific reports · 2022Article
- New insights into pathogenesis of IgA nephropathy.International urology and nephrology · 2022Review
- Host gene effects on gut microbiota in type 1 diabetes.Biochemical Society transactions · 2022Review
- Identifying celiac disease-related chemicals by transcriptome-wide association study and chemical-gene interaction analyses.Frontiers in genetics · 2022Article
- From Disease and Patient Heterogeneity to Precision Medicine in Type 1 Diabetes.Frontiers in medicine · 2022Review
- Leveraging diet to engineer the gut microbiome.Nature reviews. Gastroenterology & hepatology · 2021Review
- Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.Inflammopharmacology · 2021Review
- CRISPR-based genome editing in primary human pancreatic islet cells.Nature communications · 2021Article
- Human immunology and immunotherapy: main achievements and challenges.Cellular & molecular immunology · 2021Review
- Formation of Autoimmune Lesions Is Independent of Antibiotic Treatment in NOD Mice.International journal of molecular sciences · 2021Article
- IL-6 in inflammation, autoimmunity and cancer.International immunology · 2021Review
- The β-Cell Genomic Landscape in T1D: Implications for Disease Pathogenesis.Current diabetes reports · 2021Review
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genome-wide association studies are transformative in revealing the polygenetic basis of common diseases, with autoimmune diseases leading the charge. Although the field is just over 10 years old, advances in understanding the underlying mechanistic pathways of these conditions, which result from a dense multifactorial blend of genetic, developmental and environmental factors, have already been informative, including insights into therapeutic possibilities. Nevertheless, the challenge of identifying the actual causal genes and pathways and their biological effects on altering disease risk remains for many identified susceptibility regions. It is this fundamental knowledge that will underpin the revolution in patient stratification, the discovery of therapeutic targets and clinical trial design in the next 20 years. Here we outline recent advances in analytical and phenotyping approaches and the emergence of large cohorts with standardized gene-expression data and other phenotypic data that are fueling a bounty of discovery and improved understanding of human physiology.
Indexed as
Identifiers
29925982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.